Charles River Laboratories Inte (CRL) Stock Analysis
Falling Knife setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $164.72: Quality below floor (2.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 11%; Elevated put/call ratio: 2.15; Below-average business quality.
Charles River Laboratories provides contract research services for drug discovery and non-clinical development, including safety assessment, bioanalytical, and manufacturing services to pharmaceutical and biotech clients globally. Revenue is from long-term contracts and... Read more
Sell if holding. Engine safety override at $164.72: Quality below floor (2.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 11%; Elevated put/call ratio: 2.15; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 39, MACD bearish. Score 4.4/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliernon-human primate supply (limited source)10-K Item 1A: 'Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business'
Material Events(8-K, last 90d)
- 2026-02-18Item 5.02MEDIUMGlenn Coleman appointed Corporate EVP and CFO with tentative start date April 6, 2026. Previously CFO/CAO of Premier Inc. and CFO of DENTSPLY SIRONA. Successor named; clean handoff.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Revenue shrinking — -0.8% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -3.6%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $164.72: Quality below floor (2.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 11%; Elevated put/call ratio: 2.15; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 39, MACD bearish. Prior stop was $156.68. Score 4.4/10, moderate confidence.
Take-profit target: $179.40 (+8.9% upside). Prior stop was $156.68. Stop-loss: $156.68.
Concentration risk — Supplier: non-human primate supply (limited source); Quality below floor (2.7 < 4.0).
Charles River Laboratories Inte trades at a P/E of N/A (forward 13.3). TrendMatrix value score: 7.7/10. Verdict: Sell.
23 analysts cover CRL with a consensus score of 3.9/5. Average price target: $199.
What does Charles River Laboratories Inte do?Charles River Laboratories provides contract research services for drug discovery and non-clinical development,...
Charles River Laboratories provides contract research services for drug discovery and non-clinical development, including safety assessment, bioanalytical, and manufacturing services to pharmaceutical and biotech clients globally. Revenue is from long-term contracts and fee-for-service arrangements; the company is executing a comprehensive strategic review of its business and prospects.